<DOC>
	<DOCNO>NCT00185679</DOCNO>
	<brief_summary>To assess proportion patient donor neutrophil engraftment within 30 day allogeneic transplant . To assess incidence acute GvHD first 100 day transplantation .</brief_summary>
	<brief_title>Haploid Allogeneic Transplant Using CliniMACS System</brief_title>
	<detailed_description>To assess proportion patient donor neutrophil engraftment within 30 day allogeneic transplant ; assess incidence acute GvHD first 100 day transplantation ; assess platelet engraftment , graft failure , chronic GvHD , clinical safety , devise performance .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>RECIPIENT INCLUSION CRITERIA Histopathologicallyconfirmed diagnosis hematological lymphatic malignancy , define one following : Acute myeloid leukemia ( AML ) primary refractory disease , relapse Acute leukemia first remission poor risk factor molecular prognosis AML 5,7 , ( 6 ; 9 ) , tri8 , 11 Acute lymphocytic / lymphoblastic leukemia ( ALL ) Phil+ ( 9 ; 22 ) , ( q34 ; q11.2 ) , ( 4:11 ) ( q21 ; 23 ) Chronic myelogenous leukemia ( CML accelerate , second chronic phase Myelodysplastic syndrome high intermediate high risk category NonHodgkin 's lymphoma ( NHL ) Chronic lymphocytic leukemia ( CLL ) , Refractory &lt; 50 year old time registration Donor relate Donor genotypicallymatched haploidentical HLAA , B , C DRB1 , DQ loci Donor differs 2 3 HLA allele unshared haplotype GvHD direction No HLAmatched sibling match unrelated donor identify ECOG performance status 2 LVEF &gt; 45 % DLCO &gt; 50 % correct hemoglobin Serum creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 50 mL/min serum creatinine 1.5 mg/dL serum bilirubin &lt; 2.0 mg/dL ALT &lt; 2x ULN ( unless secondary disease ) Females childbearing potential must negative serum urine betaHCG test within 3 week registration No prior cancer within 5 year exception surgicallycured , nonmelanoma skin cancer situ cancer cervix No prior myeloablative therapy transplant Dulyexecuted inform consent RECIPIENT EXCLUSION CRITERIA Suitable candidate autologous transplantation Participation investigational drug device trial might influence study endpoint Evidence active hepatitis Evidence active cirrhosis HIVpositive History invasive aspergillosis Presence uncontrolled , active infection , ie , bacterial , viral fungal Uncontrolled CNS involvement Documented allergy murine protein Documented allergy iron dextran Lactating female Female childbearing potential unwilling implement adequate birth control Medical problem / neurologic/psychiatric dysfunction would impair his/her ability compliant medical regimen and/or tolerate transplantation , opinion principal investigator Medical problem / neurologic/psychiatric dysfunction would prolong hematologic recovery place recipient unacceptable risk , opinion principal investigator would . DONOR INCLUSION CRITERIA Age &lt; 60 year Weight &gt; 25 kg Medical history physical examination confirm good health status define institutional standard Within 30 day apheresis collection , seronegative HIV assess HIV Ag ; HIV 1+2 Ab ; HTLV I/II Ab Within 30 day apheresis collection , seronegative hepatitis assess HBsAg ; HBcAb ( IgM IgG ) ; HCV Ab Within 30 day apheresis collection , seronegative syphilis assess RPR Genotypically haploidentical determine HLA type Female donor childbearing potential must negative serum urine betaHCG test within 3 week mobilization Capable undergoing leukapheresis Has adequate venous access Willing undergo insertion central catheter leukapheresis via peripheral vein inadequate Agreeable second donation PBPC ( bone marrow harvest ) recipient fail demonstrate sustain engraftment follow transplant Dulyexecuted inform consent Screened CMV seroreactivity Must seronegative donor recipeint seronegative . Otherwise donor select ability NK cell alloreactivity base upon HLA type result donor capable NK cell alloreactivity use preferentially . DONOR EXCLUSION CRITERIA Evidence active infection ( include urinary tract infection , upper respiratory tract infection ) Evidence hepatitis ( screen ) Medical , physical psychological reason make donor unlikely tolerate cooperate growth factor therapy leukapheresis Factors place donor increase risk leukapheresis GCSFrelated complication Lactating female Female childbearing potential unwilling implement adequate birth control HIVpositive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>